Literature DB >> 15944310

Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells.

Maureen N Ajuebor1, Alex I Aspinall, Feng Zhou, Tai Le, Yang Yang, Stefan J Urbanski, Stéphané Sidobre, Mitchell Kronenberg, Cory M Hogaboam, Mark G Swain.   

Abstract

Fulminant liver failure (FLF) consists of a cascade of events beginning with a presumed uncontrolled systemic activation of the immune system. The etiology of FLF remains undefined. In this study, we demonstrate that CCR5 deficiency promotes the development of acute FLF in mice following Con A administration by preventing activated hepatic CD1d-restricted NKT cells (but not conventional T cells) from dying from activation-induced apoptosis. The resistance of CCR5-deficient NKT cells from activation-induced apoptosis following Con A administration is not due to a defective Fas-driven death pathway. Moreover, FLF in CCR5-deficient mice also correlated with hepatic CCR5-deficient NKT cells, producing more IL-4, but not IFN-gamma, relative to wild-type NKT cells. Furthermore, FLF in these mice was abolished by IL-4 mAb or NK1.1 mAb treatment. We propose that CCR5 deficiency may predispose individuals to the development of FLF by preventing hepatic NKT cell apoptosis and by regulating NKT cell function, establishing a novel role for CCR5 in the development of this catastrophic liver disease that is independent of leukocyte recruitment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944310     DOI: 10.4049/jimmunol.174.12.8027

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  The role of chemokines in the recruitment of lymphocytes to the liver.

Authors:  Ye H Oo; Shishir Shetty; David H Adams
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

2.  Chemokine complexity: the case for CCL5.

Authors:  Mitchell H Grayson; Michael J Holtzman
Journal:  Am J Respir Cell Mol Biol       Date:  2006-08       Impact factor: 6.914

Review 3.  Immune Cell Trafficking to the Liver.

Authors:  Sulemon Chaudhry; Jean Emond; Adam Griesemer
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

4.  V(alpha)14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy.

Authors:  Maureen N Ajuebor; Qingling Chen; Robert M Strieter; Patrick A Adegboyega; Tak Yee Aw
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

5.  Extracellular adenosine controls NKT-cell-dependent hepatitis induction.

Authors:  Meenakshi Subramanian; Radhika Kini; Manasa Madasu; Akiko Ohta; Michael Nowak; Mark Exley; Michail Sitkovsky; Akio Ohta
Journal:  Eur J Immunol       Date:  2014-02-19       Impact factor: 5.532

6.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.

Authors:  Maureen N Ajuebor; Yijun Jin; Griffin L Gremillion; Robert M Strieter; Qingling Chen; Patrick A Adegboyega
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

Review 9.  Host genetic factors and antiviral immune responses to hepatitis C virus.

Authors:  Chloe L Thio
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

10.  Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).

Authors:  W G Nichols; H M Steel; T Bonny; K Adkison; L Curtis; J Millard; K Kabeya; N Clumeck
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.